V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 310004931 | 310002229 | 1.73 | 81.8 | Palliative (P) | 2014-04-05 | 2014-04-25 | Sunitinib | N | N | 310024635 | TEMOZOLOMIDE |
| 310004932 | 310002229 | 1.78 | 90.3 | Not known (9) | 2017-12-20 | 2017-12-26 | Methotrexate + Folinic acid | null | N | 310024635 | MITOMYCIN |
| 310004933 | 310002230 | 1.78 | 77 | Palliative (P) | 2017-12-09 | 2017-12-11 | DA 3 + 10 | 02 | N | 310024647 | DHAP |
| 310004934 | 310002230 | 0 | 73.2 | Curative (C) | 2014-05-14 | 2014-05-16 | AC | N | N | 310024647 | CISPLATIN + FLUOROURACIL + RT |
| 310004935 | 310002230 | 1.78 | 0 | Palliative (P) | 2017-11-06 | 2017-11-29 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 310024647 | IBRUTINIB |
| 310004936 | 310002230 | 1.58 | 47.7 | Palliative (P) | 2013-03-09 | 2013-03-27 | PMitCEBO-R | 2 | N | 310024647 | CVP |
| 310004937 | 310002231 | 1.75 | 98.3 | Adjuvant (A) | 2014-08-17 | 2014-08-17 | Methotrexate 10mg/m2 po 7day | 2 | N | 310024669 | BEVACIZUMAB |
| 310004938 | 310002232 | null | 65.9 | null | 2017-02-02 | 2017-05-11 | BEAM + FLUDARABINE | N | N | 310024670 | CETUXIMAB |
| 310004939 | 310002233 | 1.81 | 76.4 | Disease modification (D) | 2017-12-31 | 2017-12-31 | DABRAFENIB | N | N | 310024704 | IRINOTECAN + TEMOZOLOMIDE |
| 310004940 | 310002234 | 1.55 | 60 | Disease modification (D) | 2014-10-02 | 2014-10-07 | RCEOP | N | N | 310024717 | CYCLOPHOSPHAMIDE + LENALIDOMIDE |
| 310004941 | 310002234 | 1.54 | null | Curative (C) | 2015-09-19 | 2015-09-19 | Methotrexate 10mg/m2 po 7day | N | N | 310024717 | CRIZOTINIB |
| 310004942 | 310002234 | 1.76 | null | Curative (C) | 2017-12-23 | 2018-01-18 | Ifosfamide PVI 1g/m2 14day | null | N | 310024717 | VINBLASTINE |
| 310004943 | 310002235 | 1.47 | null | null | 2016-05-21 | 2016-05-26 | OCTREOTIDE | N | Y | 310024729 | CVP R |
| 310004944 | 310002236 | 1.79 | 97 | Palliative (P) | 2016-12-25 | 2017-01-09 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + VINCRISTINE | N | N | 310024733 | CAPECITABINE + CARBOPLATIN |
| 310004945 | 310002237 | 1.81 | 100 | Curative (C) | 2015-10-26 | 2015-10-28 | Cytarabine HD + Methotrexate HD | 02 | N | 310024737 | CYTARABINE HD + METHOTREXATE HD |
| 310004946 | 310002238 | 1.63 | 135.7 | null | null | 2016-09-13 | Cisplatin + Docetaxel | N | N | 310024747 | CISPLATIN + DOXORUBICIN |
| 310004948 | 310002240 | 1.6 | 62 | null | 2017-11-08 | 2017-11-11 | OCTREOTIDE | 2 | null | 310024773 | FEC |
| 310004949 | 310002241 | 1.63 | 66.8 | Palliative (P) | 2016-09-21 | 2016-09-23 | Doxorubicin + Ifosfamide | 2 | N | 310024778 | CARBOPLATIN + PEMETREXED |
| 310004950 | 310002242 | 1.74 | 48.75 | Neo-adjuvant (N) | null | 2014-03-10 | Doxorubicin + Olaratumab | 02 | N | 310024784 | FCR |
| 310004951 | 310002243 | 1.54 | 72.8 | null | 2015-03-06 | 2015-03-13 | Alemtuzumab | 02 | Y | 310024785 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 310004952 | 310002243 | 0 | 82.5 | Curative (C) | 2015-11-05 | 2015-11-06 | CYCLOPHOSPHAMIDE + GEMCITABINE + VINCRISTINE | Y | N | 310024785 | IVA |
| 310004953 | 310002244 | 1.69 | 59.3 | Curative (C) | 2015-04-18 | 2015-04-18 | Fluorouracil + Folinic Acid Weekly | 2 | N | 310024793 | BEVACIZUMAB |
| 310004954 | 310002245 | 1.63 | 66.6 | Disease modification (D) | 2015-09-25 | 2015-10-13 | ICON8B TRIAL | N | N | 310024800 | DOXORUBICIN + IFOSFAMIDE |
| 310004955 | 310002246 | 1.76 | 80 | Curative (C) | 2017-07-17 | 2017-08-14 | CVP R | null | N | 310024801 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE |
| 310004956 | 310002246 | null | 90 | Palliative (P) | 2017-08-19 | 2017-08-22 | DABRAFENIB + TRAMETINIB | Y | N | 310024801 | BEVACIZUMAB |
| 310004957 | 310002246 | 1.82 | 74.95 | Palliative (P) | 2015-11-16 | 2015-11-23 | CVP R | N | N | 310024801 | CETUXIMAB + RT |
| 310004958 | 310002247 | 1.78 | 70 | Curative (C) | 2013-03-07 | 2013-03-08 | DABRAFENIB + TRAMETINIB | N | N | 310024823 | BEP |
| 310004959 | 310002248 | 1.53 | 49 | Curative (C) | null | 2016-05-21 | NEOSCOPE TRIAL | 02 | N | 310024826 | OCTREOTIDE |
| 310004960 | 310002249 | 1.79 | 71 | Curative (C) | 2015-04-27 | 2015-05-04 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | 310024828 | IVAC |
| 310004961 | 310002249 | 1.73 | 77 | Palliative (P) | 2015-02-13 | 2015-02-23 | ALL UKALL2011 IndB Std Dex (PegAsp) | N | N | 310024828 | CVP R |
| 310004962 | 310002249 | 1.54 | 85 | Palliative (P) | 2016-07-18 | 2016-07-22 | EC | 2 | N | 310024828 | CVP R + GEMCITABINE |
| 310004963 | 310002250 | 1.69 | 92 | Curative (C) | 2014-12-22 | 2015-03-23 | ECarboX | 02 | N | 310024845 | NIVOLUMAB |
| 310004964 | 310002250 | null | 114.2 | null | 2017-09-10 | 2017-09-10 | PCV | N | N | 310024845 | CYCLOPHOSPHAMIDE + ETOPOSIDE + LOMUSTINE |
| 310004965 | 310009237 | 1.82 | 68.6 | Palliative (P) | 2016-01-31 | 2016-01-31 | Carboplatin + Vinorelbine IV | N | N | 310024859 | CVP R |
| 310004966 | 310010433 | 1.69 | 63 | Palliative (P) | null | 2017-09-19 | Sunitinib | N | N | 310024862 | CLADRIBINE |
| 310004967 | 310010433 | 1.65 | 74 | Disease modification (D) | 2016-01-28 | 2016-02-03 | Azacitidine | null | N | 310024862 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 310004968 | 310002251 | 1.8 | 88 | Not known (9) | 2013-10-20 | 2013-11-08 | Brentuximab Vedotin | null | null | 310024868 | INTERFERON |
| 310004969 | 310002252 | 1.83 | 99.2 | Curative (C) | 2014-01-17 | 2014-01-26 | CARBOPLATIN + RT | N | N | 310024878 | BEVACIZUMAB |
| 310004970 | 310002253 | 1.77 | 82.25 | Curative (C) | 2013-06-08 | 2013-06-13 | Cisplatin + Dacarbazine | N | N | 310024883 | PAZOPANIB |
| 310004972 | 310002254 | null | 53 | Curative (C) | 2014-03-19 | 2014-04-16 | Methotrexate High Dose (3g/m2) | N | N | 310024886 | CYCLOPHOSPHAMIDE + ETOPOSIDE + LOMUSTINE |
| 310004973 | 310002255 | 1.62 | 70 | Curative (C) | 2014-12-16 | 2015-02-03 | Sunitinib | 2 | N | 310024887 | GEMCITABINE + VINORELBINE |
| 310004974 | 310002256 | 1.55 | null | null | 2015-03-29 | 2015-04-03 | DHAP | N | N | 310024896 | IDARAM |
| 310004975 | 310002257 | 1.73 | 90.95 | Curative (C) | 2008-10-09 | 2013-06-09 | Sorafenib | N | N | 310024901 | AXITINIB |
| 310004976 | 310002257 | null | 68.5 | Palliative (P) | 2014-08-10 | 2014-08-12 | Methotrexate intrathecal | N | null | 310024901 | DOXORUBICIN + IFOSFAMIDE |
| 310004977 | 310002257 | 1.8 | 60 | Palliative (P) | 2014-05-16 | 2014-06-03 | FEC 100 | 02 | N | 310024901 | CISPLATIN + PEMETREXED |
| 310004978 | 310002258 | null | null | Curative (C) | 2014-08-01 | 2014-08-22 | Doxorubicin + Ifosfamide | 02 | N | 310024919 | BEP |
| 310004980 | 310006939 | 1.65 | 64.5 | Curative (C) | 2017-08-02 | 2017-09-13 | DABRAFENIB | N | N | 310024928 | EVEROLIMUS |
| 310004981 | 310002260 | 1.81 | 68.6 | Curative (C) | 2014-06-29 | 2014-07-12 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | 310024932 | ECARBOX |
| 310004982 | 310002260 | null | null | Curative (C) | 2015-03-31 | 2015-04-01 | METHOTREXATE | N | N | 310024932 | MITOMYCIN |
| 310004983 | 310002260 | 1.72 | 162.6 | null | 2013-12-12 | 2013-12-12 | ESHAP | 01 | N | 310024932 | DOCETAXEL |